Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3356 |
|
| Actual shortage: | 218 (6%) | |
| Anticipated shortage: | 0 (0%) | |
| Avoided shortage: | 10 (0%) | |
| Resolved: | 3128 (93%) | |
Discontinuation Reports |
359 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 335 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
62 (26%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-OLANZAPINE | 5.0MG | TABLET | Resolved | 2020-02-13 | 2020-06-02 | 106006 |
| APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2020-04-13 | 2020-06-02 | 111925 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2020-06-04 | 2020-07-28 | 116547 |
| APO-OLANZAPINE | 15.0MG | TABLET | Resolved | 2020-06-24 | 2020-12-17 | 118769 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2017-10-23 | 2017-12-20 | 26625 |
| APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2017-11-07 | 2018-01-11 | 28564 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2017-11-09 | 2018-01-10 | 28689 |
| APO-OLANZAPINE | 15.0MG | TABLET | Resolved | 2017-12-14 | 2018-04-05 | 32818 |
| APO-OLANZAPINE | 2.5MG | TABLET | Resolved | 2018-01-22 | 2018-05-23 | 36940 |
| APO-OLANZAPINE | 20.0MG | TABLET | Resolved | 2018-02-01 | 2018-05-25 | 37997 |
| APO-OLANZAPINE | 10.0MG | TABLET | Resolved | 2018-02-21 | 2018-05-01 | 40362 |
| APO-OLANZAPINE | 5.0MG | TABLET | Resolved | 2018-02-21 | 2018-05-23 | 40367 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-01-26 | 2023-02-02 | 182367 |
| APO-OLANZAPINE | 10MG | TABLET | Resolved | 2023-02-09 | 2023-06-02 | 184083 |
| APO-OLANZAPINE | 20MG | TABLET | Resolved | 2023-02-09 | 2023-06-02 | 184097 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2023-05-06 | 2023-06-02 | 191874 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-04-01 | 2022-04-29 | 157701 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-06-06 | 2022-07-11 | 162083 |
| APO-OLANZAPINE | 10MG | TABLET | Resolved | 2022-10-07 | 2022-12-05 | 171422 |
| APO-OLANZAPINE | 7.5MG | TABLET | Resolved | 2022-10-17 | 2022-12-05 | 171886 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |